Related Experiment Videos
Preferred genetic evolutionary sequences in human breast cancer: a case study
S E Shackney1, C A Smith, A A Pollice
1Division of Medical Oncology, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA.
Cytometry
|September 1, 1995
Summary
Aggressive breast cancer cells overexpressing multiple oncogenes like HER-2/neu and ras survived chemotherapy, leading to relapse. Understanding genetic evolution in tumors may guide future adjuvant therapy decisions.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Investigating the molecular mechanisms driving aggressive human breast cancer progression and therapeutic resistance.
- Understanding the role of oncogene overexpression in tumor relapse following chemotherapy.
Observation:
- Multiparameter flow cytometry was used to analyze aggressive human breast cancer cells at diagnosis and relapse.
- Aneuploid cells overexpressing HER-2/neu and ras demonstrated resistance to intensive chemotherapy.
- Tumor cells at relapse exhibited simultaneous overexpression of at least five oncogenes: HER-2/neu, ras, EGF receptor, p53, and c-myc.
Findings:
- HER-2/neu overexpression was identified as an early event in the tumor's genetic evolutionary sequence.
- Subsequent overexpression of EGF receptor and p53 protein were associated with ras overexpression.
- Tumor ploidy and individual oncogene overexpression are not reliable independent prognostic factors.
Implications:
- Characterizing the genetic evolutionary stage of tumors could enable personalized genetic staging for adjuvant therapy.
- This approach may lead to more effective treatment strategies for aggressive breast cancers.
- Further research into genetic evolutionary pathways could improve patient outcomes.